CHANGES IN HEART TYPE FATTY ACID BINDING PROTEIN (H-FABP) AND CERTAIN BIOCHEMICAL PARAMETERS DURING CHRONIC ARTERY DISEASES

Abstract

In this study, changes in heart-type fatty acid binding protein (H-FABP) and certain biochemical parameters during chronic artery diseases were investigated. Coronary artery disease (CAD) is one of the leading causes of death and morbidity in our country,which is also true for the world in general as well. CAD generally develops on the foundations of atherosclerosis. In this study, blood samples collected from patients who applied to Van Yüzüncü Yıl University Dursun Odabaş Medical Center Emergency Department and Cardiology Polyclinics with acute ischemic chest pain between January 2019 and June 2019 were evaluated. Patients were not given any drugs or other kinds of substances before sample collection. Of the patients who applied to the cardiology clinic, 24 patients with acute ischemic chest pain were diagnosed with chronic arteritis, 12 patients with cardiological problems were diagnosed with diabetes mellitus (DM), 12 patients with hypertension (HT) problems and heart complaints, and 12 healthy individuals (who were not diagnosed with diabetes, hypertension or CAD) were included as research materials. Certain markers like Troponin, CK, CK-MB, AST, ALT, LDL-Cholesterol, HDL-Cholesterol, LDH, Glucose, and Creatinine in the blood samples were biochemically determined using an autoanalyzer (Abbott ci16200),while H-FABP values were determined using ELISA method. LDL-cholesterol levels were highest in the CAD group, HDL-Cholesterol and LDH levels were high in the CAD+HT group, while CK, CK-MB, cTnI, AST, Glucose, creatinine, and H-FABP levels were found to be high in the DM+CADgroup. Meanwhile, cTnI values were increased in people with HT or DM in addition to CAD, but there was no statistical significance. LDL-cholesterol changes also did not vary significantly between the groups. Intergroup changes in other parameters examined showed the importance of CK and Glucose levels at p≤ 0.001, AST p≤ 0.002, LDH p≤ 0.003, CK-MB p≤ 0.004, HDL-Cholesterol p≤ 0.049, Creatinine p≤ 0.011, and H-FABP p≤ 0.050. In recent years, H-FABP has taken its place in the field of cardiology with increasing importance in the diagnosis of CAD and MI. The findings obtained in this study show that the H-FABP level was increased in all patients examined (except the test group), and we recommend its use as a critical and useful parameter in the field of cardiology.

Keywords

• Diabetes Mellitus
• Hypertension
• H-FABP
• Cardiac Markers
• Coronary Artery Disease

Project Number

TYL-2019-7933

References

1. [1] Haskell, W.L., Alderman, E.L., Fair, J.M., Maron, D.J., Mackey, S.F., Superko, H.R., Williams, P.T., Johnstone, I.M., Champagne, M.A., and Krauss, R.M. (1994). Effects of intensive multiple risk factor reduction on coronary ath-erosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 89, 975-990.
2. [2] Hughes, V.F., Trull, A.K., Gimson, A., Friend, P.J., and Jamieson, N. (1997). Randomized trial to evaluate the clinical benefits of serum α-glutathione-s-transferase concentration monitoring after liver transplantation. Transplantation. 64, 1446-1452.
3. [3] Setsuta, K., Seino, Y., Ogawa, T., Arao, M., and Miyatake, Y. (2002). Use of cytosolic and myofibril markers in the detec-tion of ongoing myocardial damage in patients with chronic heart failure. The American Journal of Medicine. 113, 717-722.
4. [4] Alpert, J.S., Thygesen, K., Antman, E., and Bassand, J.P. (2000). Myocardial infarction redefined-A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology. 36, 959-969.
5. [5] Glatz, J.F., Van Bilsen, M., Paulussen, R.J., Veerkamp, J.H., Van der Vusse, G.J., and Reneman, R.S. (1998). Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochimica Biophys Acta. 961, 148–152.
6. [6] Petersen, S., Peto, V., Rayner, M., Leal, J., Luengo-Fernández, R., and Gray, A. (2008). European Cardiovascular Disease Statistics: 2008 edition. London: British Heart Foundation.
7. [7] Johnstone, M.T., and Nesto, R. (2005). Diabetes mellitus and heart disease. In: Pickup JC, Williams G, editors. Joslin's Diabetes Mellitus. 14th ed. Philadelphia: Lippincott Williams and Wilkins; P. 975- 998.
8. [8] Nemet, I., Saha, P.P., Gupta, N., Zhu, W., Romano, K.A., Skye, S.M., Cajka, T., Mohan, M.L., Li, L., and Wu, Y. (2020). A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell. 180, 862–877.

9. [9] Roth, G.A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S.F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., and Alam, K. (2017). Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 70, 1–25.
10. [10] Arora, S., Stouffer, G.A., Kucharska-Newton, A.M., Qamar, A., Vaduganathan, M., Pandey, A., Porterfield, D., Blankstein, R., Rosamond, W.D., Bhatt, D.L and Caughey, and M.C. (2019). Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. Circulation. 139,1047–1056.
11. [11] Ishii, J., Wang, J.H., Naruse, H., Taga, S., Kinoshita, M., and Kurokawa, H. (1997). Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clinical Chemistry. 43, 1372–1378.
12. [12] Nakata, T., Hashimoto, A., Hase, M., Tsuchihaski, K., and Shimamoto, K. (2003). Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndromes. Cardiology. 99, 96-104.
13. [13] Wang, Y., Yang, Y., Chen, C., Wang, S., Wang, H., Jing, W., and Tao, N. (2020). One-step digital immunoassay for rapid and sensitive detection of cardiac troponin I. ACS Sens. 5,1126–1131.
14. [14] Fung, E., Järvelin, M.R., Doshi, R.N., Shinbane, J.S., Carlson, S.K., Grazette, L.P., Chang, P. M., Sangha, R.S., Huikuri, H.V., and Peters, N.S. (2015). Electrocardiographic patch devices and contemporary wireless cardiac monitoring. Front Physiol. 6, 1-49.
15. [15] Ye, X.D., He, Y., Wang, S., Wong, G.T., Irwin, M.G., and Xia, Z. (2018). Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Acta Pharmacol Sin. 39,1155–1163.
16. [16] Muehlschlegel, J.D., Perry, T.E., Liu, K.Y., Fox, A.A., Collard, C.D., and Shernan, S.K. (2010). Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery Anesthesia Analgesia. 111, PP. 1101-1109.
17. [17] Chowdhury, U.K., Malik, V., Yadav, R., Seth, S., Ramakrishnan, L., and Kalaivani, M. (2008). Myocardiyal injury in coronary artery bypass grafting: on-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release. The Journal of Thoracic and Cardiovasculer Surgery. 135, PP. 1110-11-19.
18. [18] Wodzig, K.W., Kragten, J.A., Modrzejewski, W., Gorski, J., and Van Dieijen-Visser, M.P. (1998). Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins. Clinica Chimica Acta. 272, 209-223.
19. [19] Mair, J. (1997). Cardiac troponin I and T: are enzymes still relevant as cardiac markers? Clinica Chimica Acta. 257, 99-115.
20. [20] Hermens, W.T., Pelsers, M.M.A.L., Mullers-Boumans, M.L., de Zwaan, C., and Glatz, J.F.C. (1998). Combined use of markers of muscle necrosis and fibrinogen conversion in the early differentiation of myocardial infarction and unstable angina. Clinical Chemistry. 44, 890-892.
21. [21] Davies, C.H., Harding, S.E., and Poole-Wilson, P.A. (1996). Cellular mechanisms of contractile dysfunction in human heart failure. European Heart Journal.17, 189-198.
22. [22] Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., and Cheng, W. (1997). Apoptosis in the failing heart. The New England Journal of Medicine. 336, 1131-1141.
23. [23] Van Nieuwenhoven, F.A., Kleine, A.H., Wodzig, K.W.H., Hermens, W.T., and Kragten, J.A. (1995). Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation. 92, 2548-2554.
24. [24] Dufour, D.R., Lott, J.A., Nolte, F.S., Gretch, D.R., and Koff, R.S. (2000). Diagnosis and monitoring of hepatic injury. I. Per-formance characteristics of laboratory tests. Clinical Chemistry. 46, 2027-2049.
25. [25] Trull, A.K. (2001). The clinical validation of novel strategies for monitoring transplant recipients. Clin Biochemistry. 34, 3-7.
26. [26] Platz, K.P., Mueller, A.R., Haller, G.W., Müller, C., and Wenig, M. (1997). Determination of α- and π-Gluthatione-S-transferase will improve monitoring after liver transplantation. Transplantation Proceeding 29, 2827-2829.
27. [27] Haastrup, B., Gill, S., Kristensen, SR., Jorgensen, P.J., and Glatz, J.F.C. (2002). Biochemical markers of ischemia for the early identification of acute myocardial infarction without ST segment elevation. Cardiology. 94, 254-261.
28. [28] Chan, C.P.Y., Sanderson, J.E., Glatz, J.F.C., Cheng, W.S., and Hempel, A. (2004). A superior early myocardiyal infarction marker-human heart-type fatty acid-binding protein. Zeitschrift fur Kardiologie. 93(5), 388-397.
29. [29] Newby, L.K., Goldmann, B.U., and Ohman, E.M. (2003). Troponin: an important prognostic marker and risk stratification tool in non-ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology. 41, 31-36.
30. [30] Pelsers, M.M., Chapelle, J.P., Knapen, M., Vermeer, C., and Muijtjens, A.M.M. (1999). Influence of age, sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. Clinical Chemistry. 45, 441-443.
31. [31] Katrukha, A., Bereznikova, A., and Filatov, V. (1999). Improved detection of minor ischemic cardiac injury in patients with unstable angina by measurement of cTnI and fatty acid-binding protein (FABP). Clinical Chemistry. 45, A 139.
32. [32] Pelsers, M., Hanhoff, T., van der Voort, D., de Kruijk, J., and Twijnstra, A. (2003). Tissue specific types of fatty acid-binding proteins, B- and H-FABP, as novel markers for detection of brain injury. Clinical Chemistry and laboratory Medicine. 41, P7-98.